University Of Debrecen
- Address
- lock Available on a paid plan
University of Debrecen Medical Research Center
The University of Debrecen is a comprehensive medical research institution conducting diverse clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in ophthalmology, with extensive research in retinal disorders including macular edema secondary to retinal vein occlusion and diabetic macular edema. Their portfolio includes pivotal studies evaluating novel drug delivery systems such as suprachoroidal and intravitreal therapies for vision-threatening conditions.
- Oncology research spanning multiple cancers including renal cell carcinoma, multiple myeloma, breast cancer, bladder cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, and endometrial cancer
- Dermatology and immunology studies focusing on atopic dermatitis, psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, and alopecia areata
- Gastroenterology and hepatology trials investigating ulcerative colitis, functional constipation, liver cirrhosis, and hepatic encephalopathy
- Cardiovascular and metabolic disease research including atherosclerotic cardiovascular disease and severe hypertriglyceridemia
The center maintains active research programs in immunotherapy and targeted therapy combinations, particularly evaluating pembrolizumab-based regimens across various solid tumors. They also conduct specialized studies in hematologic malignancies including essential thrombocythemia and chronic lymphocytic leukemia, as well as rare conditions such as gastrointestinal stromal tumors. The institution's comprehensive approach extends to pediatric populations, including studies in pediatric inflammatory bowel disease and RSV prevention in high-risk infants.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 30 therapeutic areas and 15 of 601 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 573 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 86 by active trials.
- 1AstraZeneca AB27active
lock +85 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB41trials
lock +60 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Debrecen
lock Showing 1 of 499 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 601 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 39 | Unknown | 2015-11-06 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.